Microba Life Sciences Limited announced that it has received approval from AusIndustry for two separate applications for Advanced Overseas Findings for overseas research and development expenditure associated with its Inflammatory Bowel Disease (IBD) and Immuno-oncology programs. These two new Advanced Overseas Findings are in addition to the two Advanced Overseas Findings that were announced to the ASX on 22 July 2022 for eligible overseas expenditure up to $13,400,000. The two Advanced Overseas Findings cover total overseas expenditure of an estimated $1,210,000 and may result in additional R&D Tax Incentive cash rebates to the Company of $526,000. The findings cover financial years 2023, 2024 and 2025 and mean that these eligible overseas research and development expenditures related to Microba's IBD and Immuno- oncology programs, in addition to eligible Australian expenditure, will receive a 43.5% cash rebate under the Australian Federal Government's R&D Tax Incentive Program.